BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of  William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to o ...

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of William “BJ” Jones to its board of directors. Mr. Jones brings 30 years of U ...

BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PST. A live webcast of the event can be ...

Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a b ...

Financial Performance - The company reported a net loss of $34.8 million for the three months ended September 30, 2024, compared to a net loss of $32.5 million for the same period in 2023, representing a 7% increase in losses [76]. - Net loss for the nine months ended September 30, 2024, was $89.6 million, a decrease of $16.7 million, or 16%, compared to a net loss of $106.3 million in 2023 [89]. - Cash used in operating activities was $82.0 million for the nine months ended September 30, 2024, compared to $97.7 million in the same period in 2023 [93]. - Interest and other income, net, increased by 101% to $4.6 million for the three months ended September 30, 2024, compared to $2.3 million in 2023 [84]. - Interest and other income increased by $4.6 million, or 63%, for the nine months ended September 30, 2024, compared to the same period in 2023, primarily due to higher average cash balances and favorable interest rates [91]. - Total operating expenses decreased by $12.1 million, or 11%, to $101.6 million for the nine months ended September 30, 2024, compared to $113.7 million in 2023 [89]. Research and Development - Research and development expenses increased by $2.2 million, or 8%, to $30.1 million for the three months ended September 30, 2024, primarily due to increased consulting and professional services costs [86]. - Research and development expenses decreased by $14.4 million, or 16%, to $76.1 million for the nine months ended September 30, 2024, primarily due to reduced costs in clinical services and contract manufacturing [89]. - ANX005, the lead candidate for Guillain-Barré Syndrome, showed positive results in a pivotal Phase 3 trial, with patients recovering faster and more completely [74]. - ANX007 for Geographic Atrophy has initiated patient dosing in a global pivotal Phase 3 trial, with topline data expected in the second half of 2026 [75]. - ANX1502, a novel oral small molecule inhibitor, is in a proof-of-concept study for cold agglutinin disease, with initial data expected in the first quarter of 2025 [75]. - The company expects future research and development expenses to increase as it advances product candidates through late-stage clinical trials and prepares for commercialization [100]. Cash and Financing Activities - Cash and cash equivalents and short-term investments totaled $340.1 million as of September 30, 2024 [76]. - The company raised net proceeds of approximately $116.8 million in June 2024 through the sale of common stock and pre-funded warrants [102]. - In July 2022, the company raised approximately $122.5 million through the sale of 9,013,834 shares of common stock and warrants [104]. - Cash provided by financing activities was $156.2 million for the nine months ended September 30, 2024, significantly up from $17.9 million in 2023 [98]. - The company sold 7,576,067 shares under the 2021 ATM program for net proceeds of approximately $38.4 million during the nine months ended September 30, 2024 [108]. - The 2024 ATM program has a maximum offering of $100.0 million, with no sales made as of September 30, 2024, but 750,000 shares were sold post this date for net proceeds of approximately $4.5 million [107]. - The weighted-average exercise price for pre-funded warrants exercised during the nine months ended September 30, 2024 was $0.307 [105]. - The company issued 2,582,557 shares upon the cashless exercise of pre-funded warrants in March 2023 [104]. - The company had 22,113,062 pre-funded warrants outstanding as of September 30, 2023 [106]. - The 2021 ATM program registration expired on August 15, 2024, prohibiting further sales under this program [108]. Accumulated Deficit and Financial Position - The company has an accumulated deficit of $662.1 million as of September 30, 2024 [76]. - As of September 30, 2024, the company had available cash and cash equivalents of $340.1 million and an accumulated deficit of $662.1 million [92]. Accounting and Market Risk - The company has not made any material changes to its critical accounting policies as of September 30, 2024 [110]. - There were no quantitative and qualitative disclosures about market risk applicable for the company [112].

Exhibit 99.1 Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atrophy (GA); Topline Data Expected Second Half 2026 Proof-of-Concept Study with First-in-Kind Oral C1s Inhibitor AN ...

Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atrophy (GA); Topline Data Expected Second Half 2026 Proof-of-Concept Study with First-in-Kind Oral C1s Inhibitor ANX1502 Transitioned to an Enhanced Tablet Formulation; Data in Cold Agglutinin Disease (CAD) Expected in First Q ...

BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT. A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at ww ...

Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX007 in geogr ...

On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104. Following this transaction, the insider now owns 22,400 shares of the company. Annexon Inc focuses on the development of therapeutics for autoimmune and neurodegenerative disorders. The company's approach targets the classical complement pathway to prevent abnormal activation, which is a cause of the ...